Drug General Information (ID: DDIAW3H5TL)
Drug Name			Bexarotene		Drug Info		Insulin glulisine		Drug Info
Drug Type		Small molecule				Hormones
Therapeutic Class		Antineoplastics				Antidiabetic Agents
Structure

Mechanism of Bexarotene-Insulin glulisine Interaction (Severity Level: Moderate)
Increased risk of hypoglycemia Click to Show/Hide Mechanism Graph
Drug Name		Bexarotene				Insulin glulisine
Mechanism		Hypoglycemic effects				Hypoglycemic effects
Key Mechanism Factor 1
		Factor Name		Hypoglycemia
		Factor Description		Hypoglycemia is a condition in which your blood sugar (glucose) level is below the standard range. It causes irregular or rapid heartbeat, pale skin, numbness of the lips, tongue or cheeks, and sweating.
Mechanism Description		Increased risk of hypoglycemia by the combination of Bexarotene and Insulin glulisine

Recommended Action
Management		Close monitoring for the development of hypoglycemia is recommended if bexarotene is coadministered with insulin or another antidiabetic agent, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic or insulin dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when bexarotene is withdrawn.

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
3	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA."